repirinast

Repirinast is an orally administered small molecule antiallergic drug developed by Mitsubishi Chemical Corporation and first marketed in Japan in 1987 for the treatment of asthma and other allergic conditions such as hay fever. It acts primarily as a mast cell stabilizer and histamine release inhibitor. After oral administration, repirinast is rapidly hydrolyzed to its active metabolite MY1250 (deesterified repirinast), which inhibits the release of chemical mediators from mast cells triggered by IgE-antigen complexes. This mechanism helps prevent allergic responses and inflammation. Unlike typical antihistamines that block histamine receptors directly, repirinast prevents mast cell degranulation and mediator release upstream in the allergic cascade. More recently, it has been investigated for potential use in treating kidney inflammation and fibrosis due to its ability to inhibit proinflammatory mediator release from mast cells[1][6][7].

Brand names

Romet

Other names

RepirinastumRepirinastum [INN-Latin]3-methylbutyl 7,8-dimethyl-4,5-dioxo-6H-pyrano[3,2-c]quinoline-2-carboxylateIsopentyl 7,8-dimethyl-4,5-dioxo-5,6-dihydro-4H-pyrano[3,2-c]quinoline-2-carboxylateMY1250 (active metabolite)